RB1 and triple-negative breast carcinoma: This specificity was confirmed using IHC on 22Rv1 cell pellets treated with RB1 targeting or nontargeting control siRNA, and cells from the RB1-negative triple negative breast cancer (TNBC) cell line MDA-MB-468 (24) (Supplemental Figure 4B).